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The prevention of amyloid aggregation is promising for the treatment of age-related diseases such as Al-
zheimer’s (AD) and type 2 diabetes (T2D). Ten antioxidant ﬂavonoids isolated from the medicinal halophyte 
Tamarix gallica were tested for their amyloid aggregation inhibition potential. Glucuronosylated ﬂavonoids 
show relatively strong inhibitory activity of Amyloid β (Aβ) and human islet amyloid polypeptide (hIAPP) 
aggregation compared to their aglycone analogs. Structure–activity relationship of the ﬂavonoids suggests 
that the catechol moiety is important for amyloid aggregation inhibition, while the methylation of the car-
boxyl group in the glucuronide moiety and of the hydroxyl group in the aglycone ﬂavonoids decreased it.
Key words amyloid aggregation; glucuronosylated ﬂavonoid; Tamarix gallica; Alzheimer’s disease; type 2 
diabetes
The incidence of both disturbances Alzheimer’s disease 
(AD) and type 2 diabetes (T2D) is increasing and has become 
a major public health concern in many industrialized coun-
tries. Despite intense research, best strategies to treat/prevent 
these costly diseases are still under investigation. However, 
it is now widely recognized that AD and T2D share many 
pathophysiological features including increased oxidative 
stress and amyloid aggregation.1–4)
Amyloid β (Aβ) is the component of the amyloid deposits 
in the AD brain,5) while the component of the amyloidogenic 
peptide deposit in the diabetic pancreatic islets of Langerhans 
is identiﬁed as islet amyloid polypeptide (IAPP), a 37-amino 
acid peptide.6,7) Although the amino acid sequences of amy-
loidogenic proteins are diverse, they all adopt a similar struc-
ture in aggregates called cross-β-spine.8) Extensive studies in 
the past years have found that, similar to Aβ1–42, IAPP forms 
early intermediate assemblies as spherical oligomers9,10) that 
are recognized by soluble Aβ oligomers antibody,11) implicat-
ing that these oligomers possess a common folding pattern or 
conformation.4) The similarities in Aβ1–42 and IAPP oligomers 
can be used to investigate the prevention of oxidative stress 
and amyloid aggregation inhibition related to AD and T2D, 
since potent therapeutic agents such as antioxidants with a cat-
echol moiety, proved to inhibit Aβ aggregation,12–16) may play 
a key role inhibiting the aggregation of human IAPP (hIAPP) 
in case of patients with diabetes.
The powerful antioxidant activity of the medicinal halo-
phyte Tamarix gallica L. has been reported as exhibiting a 
remarkable spectrum of biochemical and pharmacological 
activities. Although traditionally used for the treatment of 
various liver disorders and marketed as a herbal medicine in 
many countries,17–19) there have been no reports on the use 
of this plant for the treatment or prevention of AD or T2D. 
Therefore, the aim of this research is to investigate the protec-
tive effect of T. gallica towards both disturbances by isolation 
and identiﬁcation of the Aβ and hIAPP aggregation inhibitors 
with antioxidant potential.
MATERIALS AND METHODS
Materials  The aerial part of T. gallica was collected at 
Tunisia. The voucher specimen (UT-ARENA-01097) is main-
tained at Alliance for Research on North Africa (ARENA), 
University of Tsukuba. Forty two-Mer amyloid β-protein 
(Aβ1–42) was synthesized by the standard protocol.20) hIAPP 
(Amylin 1–37, human, purity >95%) was purchased from 
KareBay Biochem Inc., U.S.A.
Isolation and Identiﬁcation of Flavonoids  Dried and 
crushed aerial parts (200 g) of T. gallica were extracted with 
70% ethanol and kept at room temperature for 24 h. After 
ﬁltration, the solvent of the extract was evaporated, and 
partitioned into CHCl3 (200 mL×2), EtOAc (200 mL×3), 
BuOH (200 mL×3), and H2O (200 mL). The CHCl3 layer 
(TGC, 1.1 g) was chromatographed on a silica gel column 
(ϕ3.0×35 cm, Nacalai Tesque, Inc., Japan) with acetone–hex-
ane (0 : 100→100 : 0), which yielded eight fractions, TGC-1–8. 
TGC-5 (299.4 mg) eluted with acetone–hexane (40 : 60) was 
puriﬁed by octadecyl-silane (ODS) HPLC [TSKgel ODS-
80Ts (ϕ4.6×250 mm, Tosoh Corporation, Japan), ﬂow rate 
1.0 mL/min; MeCN/H2O–0.1% triﬂuoroacetic acid (TFA) (5 
: 95→30 : 70→40 : 60→40 : 60→55 : 54→100 : 0); detection UV 
(210, 254, 280 nm)] to yield naringenin (1, 3.4 mg, tR 41 min), 
quercetin21) (2, 1.2 mg, tR 43 min), rhamnetin21) (3, 2.9 mg, tR 
46 min), and rhamnazin22) (4, 1.6 mg, tR 72 min). Tamarixetin21) 
(5, 2.0 mg, tR 37 min) was puriﬁed from TGC-6 (100.1 mg) 
using ODS HPLC [TSKgel ODS-80Ts (ϕ4.6×250 mm), ﬂow 
rate 1.0 mL/min; MeCN/H2O–0.1% TFA (5 : 95→30 : 70→40 : 6
0→40 : 60→55 : 54→100 : 0); detection UV (210, 254, 280 nm)]. 
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The EtOAc-soluble portion (TGE, 987 mg) was eluted on an 
ODS column (Cosmosil 75 C18-PREP, ϕ3.0×35 cm, Nacalai 
Tesque, Inc.) with MeOH–H2O (10 : 9→100 : 0), yielding six 
fractions, TGE-1–6. TGE-6 (228.3 mg) eluted with MeOH–
H2O (100 : 0) was fractionated by ODS HPLC [TSKgel ODS-
80Ts (ϕ4.6×250 mm), ﬂow rate 1.0 mL/min; MeOH/H2O–0.1% 
TFA (5 : 95→55 : 54→85 : 15→100 : 0); detection UV (280, 
320 nm)] to yield eight sub-fractions, TGE-6-1–8. TGE-6-8 
was identiﬁed as kaempferol23) (6, 3.3 mg, tR 37.5 min). 
TGE-6-3 (24.7 mg, tR 28.1 min) was puriﬁed by ODS HPLC 
[TSKgel ODS-80Ts (ϕ4.6×250 mm), ﬂow rate 1.0 mL/min; 
MeCN–H2O (5 : 95→25 : 75); detection UV (210, 254, 280 nm)] 
to yield quercetin 3-O-β-D-glucuronide (QGlcA)23,24) (7, 
6.3 mg, tR 9.3 min), and quercetin 3-O-β-D-glucuronide methyl 
ester (QGlcA-Me)23) (8, 9.0 mg, tR 17.6 min). Additionally, 
TGE-6-5 (20 mg, tR 32.3 min) was also puriﬁed by ODS HPLC 
[TSKgel ODS-80Ts (ϕ4.6×250 mm), ﬂow rate 1.0 mL/min; 
MeCN–H2O (5 : 95→30 : 70); detection UV (210 nm)] to yield 
kaempferol 3-O-β-D-glucuronide (KGlcA)23) (9, 2.0 mg, tR 
11.5 min), and kaempferol 3-O-β-D-glucuronide methyl ester 
(KGlcA-Me)23) (10, 5.0 mg, tR 12.3 min). The structure of these 
substances were conﬁrmed by NMR (Avance 500, Bruker, 
Germany) spectral analyses (supplementary data) and com-
pared with the literature.21–24)
Thioﬂavin-T (Th-T) Fluorescence Assay  The aggrega-
tive ability of the amyloid was evaluated at 37°C by the Th-T 
using Aβ1–42 and hIAPP. Brieﬂy, Aβ1–42 was dissolved in 0.1% 
NH4OH at 250 mM and hIAPP in 1,1,1,3,3,3-hexaﬂuoro-2-pro-
panol. The amyloid solution was diluted 10-fold with 50 mM 
phosphate buffered saline (PBS) (pH 7.4), and the solution 
was incubated with or without samples. A 2.5 µL volume of a 
peptide solution was added to 250 µL of 1 mM Th-T in 50 mM 
Gly-NaOH (pH 8.5). The ﬂuorescence intensity was mea-
sured at an excitation wavelength of 420 nm and an emission 
wavelength of 485 nm by a Multidetection Microplate Reader 
and IC50 was calculated from the inhibitory rate (%) of each 
compound (100, 10, 1 µM) on amyloid aggregation after 24 h of 
incubation. Aβ1–42 was incubated for 6, 12 and 24 h, with and 
without samples and hIAPP was incubated for 4, 8 and 24 h, 
with and without samples. Quercetin (2) was selected as the 
reference substance for this experiment.
Transmission Electronic Microscopy (TEM)  The effect 
of the ﬂavonoids on Aβ1–42 and hIAPP ﬁbrillogenesis was 
investigated by using TEM. The incubating solution was the 
same as that used for preparing the samples for Th-T assay. 
A 5 µL volume of each sample was spotted on to a glow-
discharged, Formvar-carbon-coated grid and was incubated 
for 2 min, then washed twice with 5 µL of pure water. The 
grid was negatively stained twice for 1 min each with 5 µL of 
0.4% silicotungstic acid, and the solution was removed. After 
air drying for 5 min, each sample was examined with a JEOL 
JEM-1400 electron microscope.
Determination of Antioxidant Enzyme Activity  Su-
peroxide dismutase (SOD) activity was determined with the 
use of kits obtained from Dojindo Molecular Technologies, 
Inc., Japan. The absorbance was taken at 550 nm by a spec-
trophotometer. When the samples are containing SOD, the 
superoxide anion radicals could be distinctively inhibited 
and as a result, the nitrite was reduced. The SOD activity of 
samples was measured according to the formula: SOD activity 
(%)=[(blank 1–blank 3)−(sample–blank 2)]/(blank 1–blank 3); 
with blank 1 being the coloring without inhibitor, blank 2 the 
sample blank and blank 3 the reagent blank. Epigallocatechin 
gallate (EGCG) was used as a positive control.
Statistical Analysis  Statistical differences between 
groups were determined using a Student’s t-test, with p<0.05 
set as the level of signiﬁcance.
RESULTS AND DISCUSSION
Amyloid aggregation inhibition and oxidative stress po-
tential were investigated using 10 ﬂavonoids (Fig. 1) puriﬁed 
from the ethyl acetate and chloroform layer of a 70% ethanol 
T. gallica extract. Some of the compounds contained a cat-
echol moiety, and others were non-catechol containing sub-
stances. The Th-T assay showed that both types of substances 
suppressed the aggregation of amyloid, but with different de-
grees. In fact, the ﬂavonoids that possessed a catechol moiety 
had a lower IC50 than the non-catechol type substances (Table 
1), indicating that the position and number of hydroxyl group 
on the aromatic ring is important for the determination of 
aggregation inhibition potency. This result is consistent with 
Fig. 1. Structures of Flavonoids 1–10
Table 1. IC50 of Aβ and hIAPP Aggregation Inhibitors
Substance name
IC50 (µM)
hIAPP Aβ
Naringenin (1) 10.3 9.3
Quercetin (2) 1.8 15.7
Rhamnetin (3) 13.4 131.8
Rhamnazin (4) > 100 > 200
Tamarixetin (5) 10.6 90.7
Kaempferol (6) 25.4 51.6
QGlcA (7) 1.7 3.8
QGlcA-Me (8) 22.6 31.6
KGlcA (9) 18.5 19.4
KGlcA-Me (10) 28.2 22.4
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previous reports concerning Aβ,12,13,15,16) but conﬁrmed, in this 
research, for hIAPP aggregation inhibition.
From Table 1, it was deduced that among all the isolated 
ﬂavonoids, QGlcA (7) showed the strongest effect with an IC50 
equal to 3.8 and 1.7 µM towards Aβ and hIAPP, respectively, 
leading to the conclusion that the glucuronide moiety consid-
erably increases the inhibition potential of the aglycone form. 
Structure–activity relationship of those compounds (Table 1) 
suggests that, apart from the catechol moiety, a carboxyl moi-
ety in the sugar and the presence or absence of a double bond 
between C2 and C3 in the C-ring are important functional 
groups for amyloid aggregation inhibition. Furthermore, O-
methylation signiﬁcantly reduces the inhibition potential of the 
aglycone form (2).
TEM images of Aβ and hIAPP ﬁbrils, in the presence of 
QGlcA (7), the aglycone form quercetin (2), and the methyl-
ated analogue QGlcA-Me (8) show that ﬁbril formation was 
relatively strongly inhibited by 7 (Figs. 2B, 3B) compared to 2 
(Figs. 2C, 3C) and 8 (Figs. 2D, 3D).
Biological effects of reactive oxygen species (ROS) are con-
trolled in vivo by a wide spectrum of enzymatic and non-en-
zymatic defense mechanisms, in particular SOD, that catalyze 
dismutation of superoxide anions to hydrogen peroxide and 
catalase, after which they convert H2O2 into molecular oxygen 
and water. The role of those enzymes as protective enzymes 
is well known and has been investigated extensively.25) The 
SOD activity of ﬂavonoids 1–10 are represented in Fig. 4, and 
the result shows that rhamnazin (4), tamarixetin (5), QGlcA 
(7), QGlcA-Me (8), and KGlcA (9) have the highest inhibition 
percentage. The antioxidant potential of QGlcA (7) correlated 
with its amyloid aggregation inhibition potential, proving that 
it can be also used for the prevention of oxidative stress.
The present in vitro study reports, for the ﬁrst time, that 
QGlcA (7) and KGlcA (9) function as hIAPP aggregation 
inhibitors and suggests that the ﬂavonoids with catechol and 
glucuronide moieties, that show Aβ aggregation inhibition, 
can also be used for hIAPP aggregation prevention. Extending 
this study to other amyloidogenic diseases would also be of 
interest.
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Fig. 2. TEM Observation of Aβ Aggregation Inhibition Activity
Twenty ﬁve micromolar Aβ (A), 25 µM Aβ with 100 µM QGlcA (7) (B), 25 µM Aβ with 100 µM quercetin (2) (C) and 25 µM Aβ with 100 µM QGlcA-Me (8) (D) after 24 h 
of incubation.
Fig. 3. TEM Observation of hIAPP Aggregation Inhibition Activity
Twenty ﬁve micromolar hIAPP (A), 25 µM Aβ with 100 µM QGlcA (7) (B), 25 µM Aβ with 100 µM quercetin (2) (C) and 25 µM Aβ with 100 µM QGlcA-Me (8) (D) after 
24 h of incubation.
Fig. 4. Superoxide Dismutase (SOD) Activity of Flavonoids 1–10 
(50 µM)
The results expressed as the mean±S.E.M.; n=3. * p<0.05; compared with 
EGCG ((+) control).
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